Are AMPA Receptor Positive Allosteric Modulators Potential Pharmacotherapeutics for Addiction?

Positive allosteric modulators (PAMs) of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors are a diverse class of compounds that increase fast excitatory transmission in the brain. AMPA PAMs have been shown to facilitate long-term potentiation, strengthen communication between v...

Full description

Bibliographic Details
Main Authors: Lucas R. Watterson, M. Foster Olive
Format: Article
Language:English
Published: MDPI AG 2013-12-01
Series:Pharmaceuticals
Subjects:
Online Access:http://www.mdpi.com/1424-8247/7/1/29
id doaj-a5b2f302dd7f49e28ada1234b24c005a
record_format Article
spelling doaj-a5b2f302dd7f49e28ada1234b24c005a2020-11-25T03:41:51ZengMDPI AGPharmaceuticals1424-82472013-12-0171294510.3390/ph7010029ph7010029Are AMPA Receptor Positive Allosteric Modulators Potential Pharmacotherapeutics for Addiction?Lucas R. Watterson0M. Foster Olive1Department of Psychology, Behavioral Neuroscience Area, Arizona State University, Tempe, AZ 85287, USADepartment of Psychology, Behavioral Neuroscience Area, Arizona State University, Tempe, AZ 85287, USAPositive allosteric modulators (PAMs) of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors are a diverse class of compounds that increase fast excitatory transmission in the brain. AMPA PAMs have been shown to facilitate long-term potentiation, strengthen communication between various cortical and subcortical regions, and some of these compounds increase the production and release of brain-derived neurotrophic factor (BDNF) in an activity-dependent manner. Through these mechanisms, AMPA PAMs have shown promise as broad spectrum pharmacotherapeutics in preclinical and clinical studies for various neurodegenerative and psychiatric disorders. In recent years, a small collection of preclinical animal studies has also shown that AMPA PAMs may have potential as pharmacotherapeutic adjuncts to extinction-based or cue-exposure therapies for the treatment of drug addiction. The present paper will review this preclinical literature, discuss novel data collected in our laboratory, and recommend future research directions for the possible development of AMPA PAMs as anti-addiction medications.http://www.mdpi.com/1424-8247/7/1/29AMPA PAMspositive allosteric modulatorsextinctionaddiction
collection DOAJ
language English
format Article
sources DOAJ
author Lucas R. Watterson
M. Foster Olive
spellingShingle Lucas R. Watterson
M. Foster Olive
Are AMPA Receptor Positive Allosteric Modulators Potential Pharmacotherapeutics for Addiction?
Pharmaceuticals
AMPA PAMs
positive allosteric modulators
extinction
addiction
author_facet Lucas R. Watterson
M. Foster Olive
author_sort Lucas R. Watterson
title Are AMPA Receptor Positive Allosteric Modulators Potential Pharmacotherapeutics for Addiction?
title_short Are AMPA Receptor Positive Allosteric Modulators Potential Pharmacotherapeutics for Addiction?
title_full Are AMPA Receptor Positive Allosteric Modulators Potential Pharmacotherapeutics for Addiction?
title_fullStr Are AMPA Receptor Positive Allosteric Modulators Potential Pharmacotherapeutics for Addiction?
title_full_unstemmed Are AMPA Receptor Positive Allosteric Modulators Potential Pharmacotherapeutics for Addiction?
title_sort are ampa receptor positive allosteric modulators potential pharmacotherapeutics for addiction?
publisher MDPI AG
series Pharmaceuticals
issn 1424-8247
publishDate 2013-12-01
description Positive allosteric modulators (PAMs) of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors are a diverse class of compounds that increase fast excitatory transmission in the brain. AMPA PAMs have been shown to facilitate long-term potentiation, strengthen communication between various cortical and subcortical regions, and some of these compounds increase the production and release of brain-derived neurotrophic factor (BDNF) in an activity-dependent manner. Through these mechanisms, AMPA PAMs have shown promise as broad spectrum pharmacotherapeutics in preclinical and clinical studies for various neurodegenerative and psychiatric disorders. In recent years, a small collection of preclinical animal studies has also shown that AMPA PAMs may have potential as pharmacotherapeutic adjuncts to extinction-based or cue-exposure therapies for the treatment of drug addiction. The present paper will review this preclinical literature, discuss novel data collected in our laboratory, and recommend future research directions for the possible development of AMPA PAMs as anti-addiction medications.
topic AMPA PAMs
positive allosteric modulators
extinction
addiction
url http://www.mdpi.com/1424-8247/7/1/29
work_keys_str_mv AT lucasrwatterson areampareceptorpositiveallostericmodulatorspotentialpharmacotherapeuticsforaddiction
AT mfosterolive areampareceptorpositiveallostericmodulatorspotentialpharmacotherapeuticsforaddiction
_version_ 1724527908678008832